Get the Stockscreener App
13.02
2.98%
-0.40
Arcutis Biotherapeutics Inc stock is traded at $13.02, with a volume of 1.83M.
It is down -2.98% in the last 24 hours and down -0.46% over the past month.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
See More
Previous Close:
$13.42
Open:
$13.62
24h Volume:
1.83M
Relative Volume:
0.89
Market Cap:
$1.52B
Revenue:
$59.61M
Net Income/Loss:
$-262.14M
P/E Ratio:
-3.3214
EPS:
-3.92
Net Cash Flow:
$-247.49M
1W Performance:
+1.88%
1M Performance:
-0.46%
6M Performance:
+56.12%
1Y Performance:
+40.45%
1-Day Range:
$12.75
$13.94
1-Week Range:
$12.32
$13.94
52-Week Range:
$6.99
$16.20
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
13.02 | 1.52B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
(ARQT) Proactive Strategies - Stock Traders Daily
Arcutis Biotherapeutics (ARQT) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Arcutis to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Dermatology Leader Arcutis Takes Center Stage at Major Healthcare Conference - StockTitan
Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 51.64%: Read This Before Placing a Bet - MSN
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 9.5%Should You Sell? - MarketBeat
High Growth Tech Stocks To Watch In February 2025 - Yahoo Finance
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 20%Time to Buy? - MarketBeat
Fishman Jay A Ltd. MI Acquires 118,400 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains? - MSN
Health Care Roundup: Market Talk - MSN
Arcutis Biotherapeutics' (ARQT) Buy Rating Reaffirmed at Guggenheim - MarketBeat
Brokerages Set Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Target Price at $16.60 - MarketBeat
Arcutis Biotherapeutics jumps amid takeover speculation - MSN
Here's Why Arcutis Biotherapeutics (ARQT) Could be Great Choice for a Bottom Fisher - MSN
Arcutis Biotherapeutics executive sells shares worth $153,873 By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 7.7%Here's What Happened - MarketBeat
Chronic Plaque Psoriasis Market Expected to rise, 2034 | - openPR
Trend Tracker for (ARQT) - Stock Traders Daily
4 Analysts Have This To Say About Arcutis Biotherapeutics - Benzinga
Chronic Plaque Psoriasis Treatment Market Size Report 2034 | - openPR
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Masaru Matsuda Sells 8,338 Shares - MarketBeat
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Howard G. Welgus Sells 10,000 Shares - MarketBeat
Arcutis Biotherapeutics exec sells $27,597 in stock - MSN
Arcutis Biotherapeutics' senior VP Matsuda sells $105,892 in stock - MSN
Have Insiders Sold Arcutis Biotherapeutics Shares Recently? - Simply Wall St
Arcutis director Howard G. Welgus sells $127,100 in common stock - MSN
Jennison Associates LLC Raises Stock Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics executive sells shares worth $153,873 - MSN
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains. - Yahoo
Arcutis Biotherapeutics CEO Todd Watanabe sells $245,122 in shares - MSN
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis director Howard G. Welgus sells $127,100 in common stock By Investing.com - Investing.com South Africa
Insider Sell: Howard Welgus Sells 10,000 Shares of Arcutis Bioth - GuruFocus.com
Arcutis Biotherapeutics' senior VP Matsuda sells $105,892 in stock By Investing.com - Investing.com Australia
Arcutis Biotherapeutics exec sells $27,597 in stock By Investing.com - Investing.com Canada
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arcutis Biotherapeutics Inc Stock (ARQT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Watanabe Todd Franklin | See Remarks |
Feb 03 '25 |
Sale |
12.70 |
19,301 |
245,123 |
804,129 |
| Welgus Howard G. | Director |
Feb 03 '25 |
Sale |
12.71 |
10,000 |
127,100 |
141,944 |
| Burnett Patrick | See Remarks |
Feb 03 '25 |
Sale |
12.70 |
12,116 |
153,873 |
114,862 |
| Edwards Larry Todd | See Remarks |
Feb 03 '25 |
Sale |
12.70 |
2,173 |
27,597 |
135,555 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):